A part of Merck

474790 | MG-132 - CAS 133407-82-6 - Calbiochem

474790
O preço não pôde ser recuperado
Quantidade mínima necessária para ser múltipla de
Após finalização do pedido Mais informações
Você salvou ()
 
Solicitar preço
Disponibilidade limitadaDisponibilidade limitada
Em estoque 
Descontinuado
Quantidades limitadas disponíveis
Disponibilidade a ser confirmada
    Restante: será informado
      Restante: será informado
      Vai informar
      Contatar o serviço de atendimento ao cliente
      Ver preços e disponibilidade
      Click To Print This Page

      Panorama geral

      Replacement Information

      Tabela com principais espec.

      Empirical FormulaCAS #
      C₂₆H₄₁N₃O₅ 133407-82-6

      Preço e Disponibilidade

      Número de catálogoDisponibilidade Embalagem Qtde/Emb. Preço Quantidade
      US1474790-1MG
      Verificando a disponibilidade...
      Disponibilidade limitadaDisponibilidade limitada
      Em estoque 
      Descontinuado
      Quantidades limitadas disponíveis
      Disponibilidade a ser confirmada
        Restante: será informado
          Restante: será informado
          Vai informar
          Contatar o serviço de atendimento ao cliente

          Frasco de vidro 1 mg
          Recuperando preço...
          O preço não pôde ser recuperado
          Quantidade mínima necessária para ser múltipla de
          Após finalização do pedido Mais informações
          Você salvou ()
           
          Solicitar preço
          US1474790-5MG
          Verificando a disponibilidade...
          Disponibilidade limitadaDisponibilidade limitada
          Em estoque 
          Descontinuado
          Quantidades limitadas disponíveis
          Disponibilidade a ser confirmada
            Restante: será informado
              Restante: será informado
              Vai informar
              Contatar o serviço de atendimento ao cliente

              Frasco de vidro 5 mg
              Recuperando preço...
              O preço não pôde ser recuperado
              Quantidade mínima necessária para ser múltipla de
              Após finalização do pedido Mais informações
              Você salvou ()
               
              Solicitar preço
              Description
              OverviewA potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable strains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1), which initiates apoptosis. Inhibits NF-κB activation (IC50 = 3 µM). Also reported to increases the survival rate of mesenchymal stem cells following their transplantation. Prevents β-secretase cleavage. A 10 mM (1 mg/210 µl) solution of MG-132 (Cat. No. 474791) in DMSO is also available. This material is ≥98% pure by HPLC. A material with ≥95% purity by HPLC (Cat. No. 474787) is also available.
              Catalogue Number474790
              Brand Family Calbiochem®
              SynonymsCarbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              References
              ReferencesLi, Z.W. et al. 2011. Sheng Li Xue Bao. 63, 525.
              Steinhilb, M.L., et al. 2001. J. Biol. Chem. 276, 4476.
              Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Klafki, H.W., et al. 1996. J. Biol. Chem. 271, 2865.
              Lee, D.H., and Goldberg, A.L., 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J., et al. 1996. Cell 84, 769.
              Jensen, T.J., et al. 1995. Cell 83, 129.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Product Information
              CAS number133407-82-6
              ATP CompetitiveN
              FormWhite solid
              Hill FormulaC₂₆H₄₁N₃O₅
              Chemical formulaC₂₆H₄₁N₃O₅
              ReversibleY
              Structure formula Image
              Applications
              Biological Information
              Primary Targetproteasome
              Primary Target IC<sub>50</sub>3 µM against NF-κB activation
              Primary Target K<sub>i</sub>4 nM against proteasome
              Purity≥98% by HPLC
              Physicochemical Information
              Cell permeableY
              Peptide SequenceZ-Leu-Leu-Leu-CHO
              Dimensions
              Materials Information
              Toxicological Information
              Safety Information according to GHS
              Safety Information
              Product Usage Statements
              Storage and Shipping Information
              Ship Code Ambient Temperature Only
              Toxicity Standard Handling
              Storage -20°C
              Do not freeze Ok to freeze
              Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
              Packaging Information
              Transport Information
              Supplemental Information
              Specifications

              Documentation

              MSDS

              Título

              Ficha de Segurança de Produtos (MSDS) 

              Certificados de análise

              TítuloNúmero do lote
              474790

              Referências

              Visão geral de referência
              Li, Z.W. et al. 2011. Sheng Li Xue Bao. 63, 525.
              Steinhilb, M.L., et al. 2001. J. Biol. Chem. 276, 4476.
              Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Klafki, H.W., et al. 1996. J. Biol. Chem. 271, 2865.
              Lee, D.H., and Goldberg, A.L., 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J., et al. 1996. Cell 84, 769.
              Jensen, T.J., et al. 1995. Cell 83, 129.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.

              Brochura

              Título
              Proteasomes Technical Bulletin

              Citações

              Título
            • Li, Z.W. et al. 2011. Sheng Li Xue Bao. 63, 525.
            • Kamynina, E., et al. 2007. Molecular and Cellular Biology 27, 1809.
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Chen, L., et al. 2005. Molecular Cancer Therapeutics 4, 1311.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Dana Ungermannova, Yuefeng Gao and Xuedong Liu. (2005) Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. Journal of Biological Chemistry 280, 30301-30309.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
            • Ficha de dados

              Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

              Revision27-February-2012 RFH
              SynonymsCarbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              DescriptionPotent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) which initiates apoptosis. Inhibits NF-kB activation (IC50 = 3 µM). Also reported to increases the survival rate of mesenchymal stem cells following their transplantation.
              FormWhite solid
              CAS number133407-82-6
              Chemical formulaC₂₆H₄₁N₃O₅
              Peptide SequenceZ-Leu-Leu-Leu-CHO
              Structure formula
              Purity≥98% by HPLC
              SolubilityDMSO (20 mg/ml) or Ethanol (20 mg/ml)
              Storage -20°C
              Do Not Freeze Ok to freeze
              Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
              Toxicity Standard Handling
              ReferencesLi, Z.W. et al. 2011. Sheng Li Xue Bao. 63, 525.
              Steinhilb, M.L., et al. 2001. J. Biol. Chem. 276, 4476.
              Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Klafki, H.W., et al. 1996. J. Biol. Chem. 271, 2865.
              Lee, D.H., and Goldberg, A.L., 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J., et al. 1996. Cell 84, 769.
              Jensen, T.J., et al. 1995. Cell 83, 129.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Citation
            • Li, Z.W. et al. 2011. Sheng Li Xue Bao. 63, 525.
            • Kamynina, E., et al. 2007. Molecular and Cellular Biology 27, 1809.
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Chen, L., et al. 2005. Molecular Cancer Therapeutics 4, 1311.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Dana Ungermannova, Yuefeng Gao and Xuedong Liu. (2005) Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. Journal of Biological Chemistry 280, 30301-30309.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.